Skip to main content
COLLEGIUM PHARMACEUTICAL, INC logo

COLLEGIUM PHARMACEUTICAL, INC — Investor Relations & Filings

Ticker · COLL ISIN · US19459J1043 LEI · 54930049FXZMTLW8D496 US Manufacturing
Open in API
Filings indexed 821 across all filing types
Latest filing 2020-02-11 Regulatory Filings
Country US United States of America
Listing US COLL

About COLLEGIUM PHARMACEUTICAL, INC

https://www.collegiumpharma.com/

Collegium Pharmaceutical, Inc. is a diversified biopharmaceutical company that develops and commercializes medicines for people with serious medical conditions. The company is focused on building a portfolio of differentiated medications. Its primary area of expertise is in pain management, where it develops products with abuse-deterrent properties designed to be safer alternatives for patients and the community.

Recent filings

Filing Released Lang Actions
305B2
Regulatory Filings Classification · 100% confidence The document is a Form T-1 filed with the SEC, titled 'Statement of Eligibility Under the Trust Indenture Act of 1939 of a Corporation Designated to Act as Trustee.' It provides detailed information about the trustee, The Bank of New York Mellon Trust Company, N.A., including regulatory authorities, corporate trust powers, affiliations, and exhibits related to the trustee's authority and condition. This form is a regulatory filing related to trustee eligibility under the Trust Indenture Act, not a financial report, earnings release, or management discussion. It does not contain financial statements or management commentary but is a compliance and eligibility statement. The document length is 4118 characters, and it is a standalone regulatory filing. Therefore, the appropriate classification is Regulatory Filings (RNS).
2020-02-11 English
424B5
Capital/Financing Update Classification · 95% confidence The document is a preliminary prospectus supplement dated February 10, 2020, related to an offering of $125,000,000 convertible senior notes due 2026. It includes detailed terms of the notes, use of proceeds, underwriting information, risk factors, and legal disclaimers. The document is a registration statement supplement filed pursuant to Rule 424b5, which is a type of prospectus supplement used in securities offerings. It is not a financial report, earnings release, or management discussion, but rather a detailed capital/financing update describing a new debt issuance and related offering terms. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering information, not just an announcement or a brief summary, supporting a high confidence in this classification.
2020-02-10 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content describes the entry into a material definitive agreement (an Asset Purchase Agreement) and a related Term Loan Financing agreement. It includes detailed descriptions of these agreements, their terms, and conditions, but does not contain financial statements or earnings data. The document is not an annual or quarterly report, nor is it an earnings release or management discussion. It is a regulatory filing announcing significant corporate transactions and financing arrangements. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length (11,632 characters) and detailed content support this classification with high confidence.
2020-02-10 English
PRIMARY DOCUMENT
Director's Dealing
2020-02-07 English
PRIMARY DOCUMENT
Director's Dealing
2020-02-07 English
PRIMARY DOCUMENT
Director's Dealing
2020-02-07 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.